We did observe differences in the incidence of CEBPA and DNMT3A mutations compared with European and American populations, which reminds us that the driver genetic landscape of AML is extremely complex, and it is important to consider ethnic background when stratifying disease risk. The gene discussed is DNMT3A; the disease is acute myeloid leukemia.